MTSL Issue 826

 Comments Off on MTSL Issue 826
May 012016
 
MTSL Issue 826

MTSL Issue 826 (dated 4/28/16) of the Medical Technology #Stock Letter from BioInvest includes the #Biotech Sector Analysis as well as updates from the following companies: #ALKS #BMRN #FPRX #INCY #IONS #NKTR #XON #ZIOP

MTSL Issue 817

 Comments Off on MTSL Issue 817
Dec 202015
 
MTSL Issue 817

Issue No. 817 (dated 12/17/15) of the Medical Technology Stock Letter from BioInvest includes the Biotech Sector Analysis as well as updates from the following companies found in the MTSL Portfolio: #ANTH #ALKS #MDCO #NKTR #NVAX #OGXI #PCRX SGMO #ZIOP

Alkermes Update (4-17-13)

 Comments Off on Alkermes Update (4-17-13)
Apr 232013
 
Alkermes Update (4-17-13)

Alkermes (4/17/13)– Positive MDD Data Supports Increased BUY LIMIT and TARGET PRICE Alkermes eleased rather positive Phase II data from ALKS 5461 for the treatment of major depressive disorder (MDD).  ‘5461 is a non-addictive opioid modulator, a combination of ALKS-33 and buprenorphine. The Phase II trial was highly statistically significant across major depression endpoints. The […]

Alkermes Update (1-18-13)

 Comments Off on Alkermes Update (1-18-13)
Jan 182013
 
Alkermes Update (1-18-13)

OUTLOOK 2013 – RAISING BUY LIMIT AND TARGET PRICE Over the past decade, Alkermes has evolved into a fully integrated company as they receive revenue from five ALKS-developed approved drugs and have established a real R&D pipeline. ALKS has emerged as a leader in the development of injectable antipsychotics that can be administered as infrequently […]

Alkermes Update (11-02-12)

 Comments Off on Alkermes Update (11-02-12)
Nov 022012
 
Alkermes Update (11-02-12)

Alkermes reported financial results for its second quarter of fiscal 2013, which ended Sept. 30, 2012, and the company provided improved financial expectations for its fiscal year 2013. Total revenues for the second quarter of fiscal 2013 increased more than 72% to $124.0 million, compared to the same period in fiscal 2012, which was attributable […]